## HALIFAX HEALTH AUDIT & FINANCE COMMITTEE

## 4:00 p.m., Wednesday, June 28, 2017 **REVISED AGENDA**

### I. CALL TO ORDER

			FS

Investment Committee Minutes portal page 4, action requested

March 27, 2017

Audit & Finance Committee Minutes portal page 5, action requested

April 26, 2017

### III. AUDIT COMMITTEE

Corporate Compliance, Shelly Shiflet

Monthly Compliance Dashboard Reports portal page 8, information only

**Internal Audit,** Bill Rushton

Audit Services Discussion and Analysis
 portal page 12, action requested

• Summary of Audit Follow

Summary of Internal Audit Report(s)

• Audit Plan Changes

### IV. FINANCE COMMITTEE

Financial Report, Eric Peburn

May 2017 portal page 22, action requested
 April 2017 portal page 47, action requested

## Acquisitions, Leases and Disposals, Kent Bailey

Capital Investment Strategy portal page 72, information only
 Capital Expenditures \$50,000 and over portal page 80, action requested

C-Arm for Operating Room \$144,930
 Retro-fit for X-ray Equipment - Port Orange Diagnostic Radiology \$99,820
 Pump Speed Control Units \$87,000
 Acute Care Rehabilitation Therapy Office Renovation \$82,400

• Soiled Utility Room Renovation for Respiratory Therapy \$72,832

Facility and Office Space Leases – Deltona

Operating Leases \$250,000 and over

Primary Care \$10,604 monthly payment
 Pediatrics \$7,168 monthly payment
 Rotating Specialists \$3,022 monthly payment
 Meeting Space \$5,313 monthly payment

• ASC \$26,417 monthly payment

 Comparison of Projected and Actual Financial portal page 94, information only Results for Significant Projects

### **Old Business**

Disposals

Meeting Request Tracker/Checklist portal page 97, none

### **New Business**

 FY 2018 Preliminary Budget Review / Not to Exceed presentation, information only Millage Rate

Deltona Schedule, Budget Status & Financing Update discussion, information only

portal page 91, action requested

portal page 92, action requested

## HALIFAX HEALTH AUDIT & FINANCE COMMITTEE

## **Information Only**

•	Discharged Based -Average Length of Stay and	portal page 115, information only
	Case Mix Index	
•	Investment Performance Reports, May & April 2017	portal page 117, information only
•	Capital Expenditures \$25,000 - \$50,000	portal page 127, information only
	Time Clock Replacement	\$49,975
	<ul> <li>Fetal Monitors for OB Diagnostics/Maternal Fetal Medicine</li> </ul>	\$37,528
	<ul> <li>Signage for Halifax Health Port Orange</li> </ul>	\$35,000
	• Sterilizer Conversion	\$33,060
	<ul> <li>Eye Surgery Stretchers</li> </ul>	\$25,014

## V. OPEN DISCUSSION

## VI. NEXT MEETING

Monday, August 7, 2017, 5:00 p.m. - France Tower Conference Room A

FY 2017 BUDGET WORKSHOP, Combined with the Board of Commissioners
WEDNESDAY, August 30, 2017, 4:00 p.m. - Regular scheduled meeting
TUESDAY, September 5, 2017, 5:05 p.m. - Tentative First Public Hearing, Board of
Commissioners

## VII. EXECUTIVE SESSION

## VIII. ADJOURN

## CAPITAL EXPENDITURES & OPERATING LEASES

Audit & Finance Committee June 28, 2017

## Capital Expenditures \$50,000 and over

DESCRIPTION	DEPARTMENT	SOURCE OF FUNDS	TOTAL
C-Arm for Operating Room	Radiology Department	Working Capital	\$144,930
Retro-fit for X-ray Equipment - Port Orange Diagnostic Radiology	Radiology Department	Working Capital	\$99,820
Pump Speed Control Units	Surgical Services	Working Capital	\$87,000
Acute Care Rehabilitation Therapy Office Renovation	Rehabilitation Services	Working Capital	\$82,400
Soiled Utility Room Renovation for Respiratory Therapy	Respiratory Therapy	Working Capital	\$72,832

## **Operating Leases \$250,000 and over**

DESCRIPTION	DEPARTMENT	REPLACEMENT Y/N	LEASE TERMS	INTEREST RATE	MONTHLY PAYMENT
	Primary Care	N	10 years	2.88%	\$10,604
Facility and Office Space	Pediatrics	N	10 years	2.88% Discount	\$7,168
Leases - Deltona	Rotating Specialists	N	10 years	Rate*	\$3,022
	Meeting Space	N	10 years	Kate	\$5,313

<sup>\*</sup>A-rated 10 year municipal bond rate



TO: Jeff Feasel, President and Chief Executive Officer

FROM: Bill Griffin, Director, Research and Planning

CC: Eric Peburn, Executive Vice President and Chief Financial Officer

DATE: June 20, 2017

RE: Facility and Office Space Leases - Deltona

An important component of Halifax Health's strategic initiative of expanding access to care for the residents of Deltona and surrounding communities is the medical office building (Deltona MOB) under development by a third-party (Landmark) on land leased from HH Holdings, Inc. The Deltona MOB will serve as a central connection for Halifax Health at the Deltona campus to patients, physicians and the community. Halifax Health is positioned to lease certain space in the MOB as outlined below. It is recommended that we seek approval for these leases from their respective affiliate boards.

The proposed space to be leased includes:

- Clinical office space to enhance access to primary care, pediatrics, and rotating specialists,
- Meeting space to accommodate general meetings, educational programs and community events, and

These leases are integral to enhancing access and support of the existing and planned facilities at the Deltona campus. Below is a summary of the lease terms.

	Primary Care	Pediatrics	Rotating Specialists	Meeting Space
Square footage	5,000	3,380	1,425	3,000
Initial year total rate/sq. ft.	\$25.45	\$25.45	\$25.45	\$21.25
Annual rent escalator %	2.50%	2.50%	2.50%	2.50%
Tenant build out allowance/sq. ft.	\$100	\$100	\$100	\$60
Term (years)	10	10	10	10
Discount Rate	2.88%*	2.88%*	2.88%*	2.88%*
Monthly Payment	\$10,604	\$7,168	\$3,022	\$5,313
NPV lease payments	\$1,216,521	\$822,368	\$346,708	\$609,455
Tenant	HCI, Inc.	HCI, Inc.	HCI, Inc.	HH Holdings, Inc.

<sup>\*</sup>A-rated 10 year municipal bond rate

Halifax Health physician practice operations are conducted by Halifax Clinical Integration, Inc. (HCI, Inc.). HCI, Inc. is owned by Halifax Healthcare Systems, Inc., which is a controlled affiliate of Halifax Hospital Medical Center (District).

## Deltona Facilities Financing Update

Presentation to the Finance Committee June 28, 2017



## Agenda

- Project Overview
- Financing Objectives and Alternatives
- Potential Financing Structures
- HMS Overview
- Financial Impact to System
- Potential Banking Partners
- JP Morgan Alternative Structure
- Next Steps

## **Project Overview**

- Free-Standing Emergency Room opened April 25, 2017
- Medical Office Building target opening date Fall 2018
- Inpatient hospital facility target opening date late calendar year 2019
- Prepared facility cost estimates and volume and financial projections
- Prepared long-range forecast with Deltona facility
- Identified financing alternatives
- Shared project details and financing scenarios with target banking institutions
- Identified real estate parcels for potential sale and obtaining appraisals
- Complete final ranking of financing options with Kaufman Hall
- Approval of Plan of Finance
  - August 30<sup>th</sup> Finance Committee meeting
  - September 5<sup>th</sup> Board of Commissioners meeting



## Financing Objectives

- A. Access to lowest cost of capital
- B. Optimize mix of borrowed funds and cash, including proceeds from sale of non-core assets
- C. Limit impact to liquidity and DSCR
- D. Maintain debt capacity of Obligated Group

## Financing Alternatives

- A. Public sale of bonds
- B. Bank loans
- C. Other financing alternatives



## Potential Financing Structures

Financing Objectives

		Α	В	С	D
Scenario	Description	Cost of Capital	Optimal Cash/Debt	Liquidity/ DSCR	OG Debt Capacity
1	\$105m Obligated Group debt				
2	\$75m Obligated Group debt, \$20m land sales and \$10m lease				
3	\$105m Deltona stand-alone debt (outside of Obligated Group)				
4	\$105m HMS debt with lease to Halifax operating entity				
5	\$75m HMS debt with lease to Halifax operating entity, \$20m land sales and \$10m lease				

Favorable			
Neutral			
Unfavorable			

## Halifax Management System, Inc. (HMS) Overview

- Not-for-profit affiliate of the District, organized in 1984
- Not a member of the Obligated Group
- Owns HHPO and two medical office facilities
- As of May 31, 2017, \$2.2 million of debt outstanding (final maturity in FY 2018)
- Scenario 4 assumes HMS debt of \$105m with lease to Halifax operating entity
- Scenario 5 assumes HMS debt of \$75m with lease to Halifax operating entity, \$20m land sales and \$10m lease

## Financial Impact to System

- Deltona I/P facility is anticipated to incur operating losses in FY 2020 and FY 2021 and achieve positive operating results thereafter
- System for FY 2020, targeting 3% operating margin excluding Deltona
- Lower FY 2020 System operating margin and DSCR

## Deltona Average Daily Census, Revenue and Adjusted Cash Flow

	FY 2020	FY 2021	FY 2022	FY 2023
Average daily patient census	18	31	47	48
Net patient service revenue	\$22.9m	\$39.5m	\$61.6m	\$63.10
Adjusted Deltona facility cash flow, before debt service/internal lease costs	\$618k	\$10.1m	\$22.2m	\$22.2m
00313	φυτοκ	\$10.1111	<b>ΦΖΖ.Ζ</b> ΙΙΙ	<b>ΦΖΖ.ΖΙΙΙ</b>
Estimated interest cost %		2% t	o 6%	
Estimated net interest cost \$		\$1.5m t	o \$6.3m	
Average principal payment \$2.5m to \$				
Estimate equipment lease cost		\$1.0m t	o \$2.0m	

## Potential Banking Partners

 J.P. Morgan – current treasury bank, letter-ofcredit provider, line-of-credit provider

Fifth-Third – no accounts or services

PNC – no accounts or services

## Next Steps

- Obtain S&P feedback
- Bond/Tax counsel and RSM feedback
- Complete due diligence with potential banking partners and evaluate financing options proposed
- Complete final ranking of financing options with Kaufman Hall
- Present final recommendation to Finance Committee and Board of Commissioners
- Begin implementation of plan of finance, with objective of having borrowed funds available between November 2017 and April 2018





**Deltona Project Financing: Securities Lending Structure Overview** 

June 2017

J.P.Morgan

The Company should consult with their internal and external accounting advisors prior to executing any transaction similar to that contemplated herein. J.P. Morgan does not provide specific accounting advice for any transaction. Many of the concepts discussed herein are highly complex and have only been summarized. The actual accounting treatment afforded any transaction executed by the Company may vary substantially from the treatment described herein, based upon, among other things, other facts and circumstances not contemplated in the summary provided.

This presentation was prepared exclusively for the benefit and internal use of the J.P. Morgan client to whom it is directly addressed and delivered (including such client's subsidiaries, the "Company") in order to assist the Company in evaluating, on a preliminary basis, the feasibility of a possible transaction or transactions and does not carry any right of publication or disclosure, in whole or in part, to any other party. This presentation is for discussion purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by J.P. Morgan. Neither this presentation nor any of its contents may be disclosed or used for any other purpose without the prior written consent of J.P. Morgan.

The information in this presentation is based upon any management forecasts supplied to us and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. J.P. Morgan's opinions and estimates constitute J.P. Morgan's judgment and should be regarded as indicative, preliminary and for illustrative purposes only. In preparing this presentation, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which was provided to us by or on behalf of the Company or which was otherwise reviewed by us. In addition, our analyses are not and do not purport to be appraisals of the assets, stock, or business of the Company or any other entity. J.P. Morgan makes no representations as to the actual value which may be received in connection with a transaction nor the legal, tax or accounting effects of consummating a transaction. Unless expressly contemplated hereby, the information in this presentation does not take into account the effects of a possible transaction or transactions involving an actual or potential change of control, which may have significant valuation and other effects.

Notwithstanding anything herein to the contrary, the Company and each of its employees, representatives or other agents may disclose to any and all persons, without limitation of any kind, the U.S. federal and state income tax treatment and the U.S. federal and state income tax structure of the transactions contemplated hereby and all materials of any kind (including opinions or other tax analyses) that are provided to the Company relating to such tax treatment and tax structure insofar as such treatment and/or structure relates to a U.S. federal or state income tax strategy provided to the Company by J.P. Morgan.

J.P. Morgan's policies prohibit employees from offering, directly or indirectly, a favorable research rating or specific price target, or offering to change a rating or price target, to a client or prospective client as consideration or inducement for the receipt of business or for compensation. J.P. Morgan also prohibits its research analysts from being compensated for involvement in investment banking transactions except to the extent that such participation is intended to benefit investors.

IRS Circular 230 Disclosure: JPMorgan Chase & Co. and its affiliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters included herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone not affiliated with JPMorgan Chase & Co. of any of the matters addressed herein or for the purpose of avoiding U.S. tax-related penalties.

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries worldwide. Securities, syndicated loan arranging, financial advisory and other investment banking activities are performed by a combination of J.P. Morgan Securities LLC, J.P. Morgan Limited, J.P. Morgan Securities plc and the appropriately licensed subsidiaries of JPMorgan Chase & Co. in EMEA and Asia-Pacific, and lending, derivatives and other commercial banking activities are performed by JPMorgan Chase Bank, N.A. J.P. Morgan deal team members may be employees of any of the foregoing entities.

This presentation does not constitute a commitment by any J.P. Morgan entity to underwrite, subscribe for or place any securities or to extend or arrange credit or to provide any other services.

This message has been prepared by personnel in or associated with the Sales and Trading Departments of one or more affiliates of JPMorgan Chase & Co. and is not the product of J.P. Morgan's Research Department. It is not a research report and is not intended as such. This material is for the general information of our clients and is a "solicitation" only as that term is used within CFTC Rule 1.71 and 23.605 promulgated under the U.S. Commodity Exchange Act.

This material was prepared by an Associated Person with responsibilities related to the marketing and sale of swaps and other derivatives. All questions related to swaps referenced in these materials must be directed to us.swaps.marketing@jpmorgan.com.

J.P.Morgan

## This material is delivered in reliance on the Municipal Advisor Rule's IRMA Exemption

(a) This material is provided to you in reliance on the Independent Registered Municipal Advisor exemption pursuant to Section 15B of the Securities Exchange Act of 1934, as amended; (b) J.P. Morgan is not acting as an advisor to you and does not owe a fiduciary duty pursuant to Section 15B of the Securities Exchange Act of 1934, as amended, to you with respect to the information and material contained in this communication; (c) J.P. Morgan is acting for its own interests; (d) You should discuss any information and material contained in this communication with any and all internal or external advisors and experts that you deem appropriate before acting on this information or material; and (e) J.P. Morgan seeks to serve as an underwriter on a future transaction and not as a financial advisor or municipal advisor. The information provided is for discussion purposes only in anticipation of being engaged to serve or in relation to our engagement as an underwriter. The primary role of an underwriter is to purchase securities with a view to distribute in an arm's-length commercial transaction. The underwriter has financial and other interests that differ from yours.

## Structured Variable Product Overview: Securities Lending Agreement


## **Structure Overview**

- HMS purchases its bonds from conduit issuer
- HMS executes a SLA with JPMorgan
  - HMS lends its bonds to JPMorgan
    - HMS receives yield on bonds held in the SLA
  - JPMorgan provides cash (100% or par) against bonds
    - HMS pays financing rate of index plus a spread
  - HMS owes the difference between par and value of bonds prior to or at maturity
- While HMS receives the yield on the bonds, JPMorgan is the tax owner of the bonds via the SLA
- SLA is governed by a Master Securities Lending Agreement ("MSLA")

### **Bond Terms / Documents**

- The fixed rate bonds lent to JPMorgan Chase Bank NA will have the following:
  - Limited Offering Memorandum
  - Bond Opinion, including unqualified tax opinion
  - Public Ratings
  - Cusip(s)
  - Initial price of Par or 100
  - Optional Redemption 1 year following closing
  - Multi-modal documents; initial fixed rate mode
  - Purchase in Lieu of Redemption

### **Product Flows**




## **SLA Terms / Documents**

- Securities Lending Agreement will be provided by JPMorgan Chase Bank NA and have the following:
  - Master Securities Lending Agreement
  - Enforceability Opinion
  - Security Package TBD
  - SLA cash will match bond par amount
  - SLA will have [7]-year maturity
  - Optional Termination after 1-year

## Full product cash flows: At bond issuance and under SLA


## **SLA Flows – At Closing**

- Conduit Issuer issues the Bonds
- HMS purchases its bonds from conduit issuer
- 3) HMS executes a Master Securities Lending Agreement (SLA) with JPMorgan:
  - HMS lends its bonds to **JPMorgan**
  - JPMorgan provides cash (100% or par) against bonds
- 4) Bond proceeds are deposited to Project Fund held by trustee
- Bond proceeds are drawn to pay Deltona Project costs



## **SLA Flows - Over Time**

- 1) HMS pays the yield on the **Bonds**
- As the tax owner of the Bonds, JPMorgan receives the yield on the Bonds
- Under the SLA, JPMorgan pays the Bond yield to HMS
- Under the SLA, HMS pays a Financing Rate to JPMorgan equal to an index + spread



- 1. Bond coupon rate is assumed to be 6% for illustrative purposes only; final bond coupon subject to market conditions and verification.
- 2, SLA rate assumed to be 20Y average of 70% 1-Month LIBOR (1.66%) plus a credit spread of 1.05%. SLA pricing preliminary and subject to change, based upon an assumed HMS rating of BBB+; security package to be determined, and final due diligence. J.P.Morgan

## HMS has three alternatives at the maturity of the Securities Lending Agreement

## Alternative 1: Amend and restate the SLA

- JPM and HMS mutually agree to amend and restate the Securities Lending Agreement (can occur before SLA maturity date)
- Amendments would include, but are not limited to:
  - Extension of the maturity date
  - Re-pricing the SLA credit spread
- JPM would anticipate maintaining ownership of the bonds

## Alternative 2: Settle the SLA & refund bonds

- HMS decides to refund the bonds in the then prevailing market
- HMS exercises its par call on the bonds and cash settles the Securities Lending Agreement
  - Given the price of the bonds will be par at the call date, there will be 0 price depreciation in the value of the bonds to be paid to JPMorgan (i.e. cash settlement equals 0)

## Alternative 3: Settle SLA & leave bonds outstanding1

- At SLA maturity HMS will owe to JPM the value of any price depreciation in the bonds
  - If rates are higher, the bond will likely be trading at a discount to par
    - The difference between the fair-market price for the bonds and par is the settlement value of the SLA
  - If rates are lower, the bond will likely be priced to the call, or par
    - There is no settlement on the SLA
- JPM may retain ownership of the bonds or alternatively may sell the bonds in the marketplace

## Sensitivity analysis of SLA settlement<sup>2</sup>

Change in Rates	Indicative Bond Price	Indicative Settlement Value				
+500 bps	55.3009	(\$46.93mm)				
1000 bp3	00.0000	(ψ+0.5511111)				
+250 bps	72.7972	(\$28.56mm)				
+100 bps	87.6128	(\$13.01mm)				
+50 bps	93.5193	(\$6.80mm)				
+25 bps	96.6840	(\$3.48mm)				
+0 bps	100.0000	\$0.00mm				
-25 bps	100.0000	\$0.00mm				
-50 bps	100.0000	\$0.00mm				
-100 bps	100.0000	\$0.00mm				
Analysis based on \$105mm notional and a hand with 22 years remaining until maturity						

<sup>&</sup>lt;sup>2</sup>Analysis based on \$105mm notional and a bond with 23 years remaining until maturity Note: Assumes that if rates are higher the bond trades to maturity and if rates are lower the bond trades at par. "Rates" refers to HMS' cost of financing (i.e. benchmark rates + HMS' credit)


<sup>&</sup>lt;sup>1</sup>"Rates" refers to HMS' cost of financing (i.e. benchmark rates + HMS' credit)


## HMS Deltona financing – indicative financing statistics Scenario 1: \$75 million Deltona construction fund deposit

Indicative Sources & Uses						
Sources:						
Bond Proceeds:	\$75,570,000					
Total Sources:	\$75,570,000					
Uses:						
Construction Fund Deposit	\$75,000,000					
Estimated Issuance Costs (0.75%)	566,775					
Additional Proceeds	3,225					
Total Uses:	\$75,570,000					

### Assumptions include:

- \$75 million construction fund deposit
- Estimated COI of 0.75% of par amount
- Interest calculated at 20Y historical average of 70% 1-Month LIBOR (1.66% as of June 26, 2017) plus a credit spread of 1.05% based upon an assumed HMS rating of BBB+; security package to be determined, and final due diligence
- Assumes closing on December 1, 2017 with first principal payment on June 1, 2020
- Bonds structured to achieve aggregate level debt service across the entire Halifax portfolio
- Assumes that structured product is renewed at the above terms at each renewal date over the life of the bonds





Debt service for variable rate Series 2008 bonds is calculated based on a principal amount of \$70 million and an assumed synthetic swap fixed payor rate of 3.837%.

nterest rates used herein are hypothetical and take into consideration conditions in today's market and other factual information such as the issuer's credit rating, geographic location and market sector. Interest rates applied herein are hypothetical, based on current market facts and should not be viewed as rates that J.P. Morgan might expect to achieve for you at the time of any relevant transaction should we be selected to act as your underwriter. Information about interest rates and terms for SLGs is based on current publicly available information and treasury or agency rates for open-market escrows are based on current market interest rates and should not be seen as costs or rates that J.P. Morgan might expect to achieve for you at the time of any relevant transaction should we be selected to act as your underwriter.


## HMS Deltona financing – indicative financing statistics Scenario 2: \$105 million Deltona construction fund deposit


indicative sources & oses	
Sources:	
Bond Proceeds:	\$105,795,000
Total Sources:	\$105,795,000
Uses:	
Construction Fund Deposit	\$105,000,000
Estimated Issuance Costs (0.75%)	793,463
Additional Proceeds	1,538
Total Uses:	\$105.795.000

Assumptions include:

Indicative Sources & Uses

- \$105 million construction fund deposit
- Estimated COI of 0.75% of par amount
- Interest calculated at 20Y historical average of 70% 1-Month LIBOR (1.66% as of June 26, 2017) plus a credit spread of 1.05% based upon an assumed HMS rating of BBB+; security package to be determined, and final due diligence
- Assumes closing on December 1, 2017 with first principal payment on June 1, 2020
- Bonds structured to achieve aggregate level debt service across the entire Halifax portfolio
- Assumes that structured product is renewed at the above terms at each renewal date over the life of the bonds





Debt service for variable rate Series 2008 bonds is calculated based on a principal amount of \$70 million and an assumed synthetic swap fixed payor rate of 3.837%.

nterest rates used herein are hypothetical and take into consideration conditions in today's market and other factual information such as the issuer's credit rating, geographic location and market sector. Interest rates applied herein are hypothetical, based on current market facts and should not be viewed as rates that J.P. Morgan might expect to achieve for you at the time of any relevant transaction should we be selected to act as your underwriter. Information about interest rates and terms for SLGs is based on current publicly available information and treasury or agency rates for open-market escrows are based on current market interest rates and should not be seen as costs or rates that J.P. Morgan might expect to achieve for you at the time of any relevant transaction should we be selected to act as your underwriter.

## Comparison of available floating rate products

	VRDBs with Bank LOC	Floating Rate Notes Public Market	Floating Rate Notes Bank Direct Purchase	Structured Variable Rate Product Securities Lending Agmt	Synthetic Variable Intermediate Fixed Rate Bond + FXR swap
Size / Capacity	<ul><li>Size may require <u>multiple</u> banks</li></ul>	<ul><li>Dependent on market conditions at pricing</li></ul>	Size may require multiple banks	JPM can single source	<ul><li>Dependent on market conditions at pricing</li></ul>
Term	Likely limited to 3Y	■ Up to 7Y	Available up to 10Y	■ Up to 7Y	Up to 30Y
Security / Covenants	■ [HMC lease term extends to t ■ Banks may require		ities/assets, including Port Orange ar  Banks may require additional	nd ambulatory facilities; HMC MT  None	□ Cross-defaults to lease;
Other non-Credit Business	additional security/ covenants  Banks may require other	None	security/ covenants  Banks may require other non-	None	None
Rating Agency Requirements	non-credit business  Rating based on LOC bank	Rating based on HMS credit	<ul><li>credit business</li><li>No rating required (some banks req. private rating)</li></ul>	Rating based on HMS credit	Rating based on HMS credit
Disclosure	<ul><li>Appendix A disclosure (HMC + HMS)</li></ul>	Appendix A disclosure (HMC + HMS)	■ No disclosure	Limited disclosure (No Appendix A)	Appendix A disclosure (HMC + HMS)
Put/Funding Risk	Optional Tender by investors Risk of failed remarketings Term-out of Bank Bonds	<ul><li>No optional tender by investors;</li><li>Renewal risk at mandatory put</li></ul>	Renewal risk at mandatory put	<ul><li>No optional tender by JPM;</li><li>If not renewed, payment of SLA settlement cost (if any)</li></ul>	No optional tender by investors; Renewal risk at mandatory put
Market Rate Risk	■ Yes	■ Yes	■ Yes	■ Yes	■ Yes
Market Access Risk	Yes, if not renewed	■ Yes	Yes, if not renewed	Limited to SLA payment, if not renewed	■ Yes
Tax Risk	■ Tax adjustment provision	■ None	■ Tax adjustment provision	■ None	None
Bank Credit Exposure	Credit of LOC bank drives rate resets	None	None	None	None
Counterparty Risk	None	■ None	None	Yes	■ Yes
Settlement Risk	■ None	■ None	None	Yes (first year only)	■ Yes
Benchmark	■ Actual Resets [~SIFMA]	SIFMA or %LIBOR	■ %LIBOR	SIFMA or %LIBOR	■ SIFMA or %LIBOR

## Considerations for using a Structured Variable Rate Product

Size	<ul> <li>Entire \$105MM financing can be executed with JPMorgan</li> <li>Total size could be pieced together across products and banks, but a consistent credit package will be challenging</li> </ul>
Variable Funding Alternatives	<ul> <li>SLA compares favorably to other 7y variable funding alternatives</li> <li>VRDB's with bank LOC</li> <li>Public market FRNs</li> <li>Bank Direct Purchase FRNS</li> <li>Public Market Fixed Rate Bonds swapped to floating</li> </ul>
Flexibility	<ul> <li>Structure is fully or partially prepayable at par after 1 year; allows flexibility to de-leverage based on future land sale proceeds</li> <li>Ease of renewal</li> <li>Limited Disclosure</li> <li>Ability to leave Fixed Rate bond outstanding following the SLA maturity / termination</li> </ul>
Security, Covenants and Other Requirements	<ul> <li>[Parity obligation and comparable legal structure with outstanding HMS Series 2010 Bonds]</li> <li>No tax adjustment provision</li> <li>No other non-credit business</li> </ul>
Settlement Risk	<ul> <li>If SLA is not renewed and the fixed rate bonds are not called at par, HMS may owe a settlement payment on the SLA</li> <li>Settlement payment occurs if fixed rate bonds are priced at a discount due to higher long term tax-exempt fixed rates</li> </ul>

Requirement		Action Items
1)	Tax Opinion	Schedule follow-up call with Bond/Tax Counsel
2)	Accounting	HMS to check accounting treatment with internal / external accountants
3)	Determine Conduit Issuing Authority	Deltona or other
4)	Due Diligence	Schedule Due Diligence call with JPM team
5)	Finalize Security	Subject to final structure and DD call
6)	Ratings	Finalize standalone rating(s) for HMS